Detalhe da pesquisa
1.
MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
Eur J Haematol
; 112(2): 296-300, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37822035
2.
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Transfusion
; 62(5): 961-973, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35452143
3.
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica
; 106(12): 3100-3106, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047178
4.
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Haematologica
; 104(8): 1565-1571, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733271
5.
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Int J Mol Sci
; 21(1)2019 12 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31881723
6.
A randomized phase II trial of azacitidine +/- epoetin-ß in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Haematologica
; 101(8): 918-25, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27229713
7.
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Br J Haematol
; 180(5): 735-737, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27977052
8.
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Haematol
; 10(7): e521-e529, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37245522
9.
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
J Clin Oncol
; 41(10): 1888-1897, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455187
10.
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.
Blood Adv
; 6(1): 1-12, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34492684
11.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Leukemia
; 36(10): 2519-2527, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071100
12.
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
J Clin Oncol
; 39(14): 1575-1583, 2021 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600210
13.
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia
; 38(4): 918-922, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368440
14.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Leukemia
; 36(11): 2739-2742, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104395
15.
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Leukemia
; 34(4): 1182-1186, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796915
16.
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Leuk Res
; 38(12): 1430-4, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25449687